Navigation Links
Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
Date:2/20/2008

NEW HAVEN, Conn., Feb. 20 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that the Company would implement a one-for-ten reverse split of its common stock, effective at 5:00 p.m. Eastern Time on Wednesday, February 20, 2008.

On a pre-split basis, Vion Pharmaceuticals has 81,017,569 shares outstanding as of February 19, 2008. As a result of the reverse stock split, every 10 shares of Vion Common Stock will be combined into one share of Vion Pharmaceuticals' Common Stock, reducing the total number of outstanding shares to approximately 8.1 million shares.

Shares held electronically through a brokerage will be automatically adjusted for the reverse split. Shareholders of record will receive a letter of transmittal from the Company's stock transfer agent, American Stock Transfer & Trust Company, with instructions about how to exchange their shares. Vion will pay cash in lieu of issuing fractional shares.

When the reverse split becomes effective, Vion Pharmaceuticals' 7.75% Convertible Senior Notes due 2012 (the "Notes") will have a conversion rate of 52.0833 shares of common stock per $1,000 Note. Holders of Vion Pharmaceuticals' warrants will receive a notice detailing post-split warrant shares and exercise prices.

Beginning on February 21, 2008, a "D" will be added to the Vion trading symbol for 20 trading days to designate that shares are trading on a post- split basis. After such time, the symbol will revert to "VION".

Alan Kessman, Chief Executive Officer, said, "This adjustment to our capital structure is important to implement in order to attempt to restore compliance with NASDAQ listing requirements, which we believe is in the best interest of our shareholders." He
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
2. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
3. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
4. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
5. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
6. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
7. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Keryx Biopharmaceuticals Announces Additions to Management Team
10. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
11. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... 6 Calbiotech, Inc. announced toda...tive Research (SBIR) Phase I contract by the U.S. ...terms of the agreement, Calbiotech will develop an...f Dengue virus. ,, Dengue virus is a mosquit...o military forces deployed to tropical areas of th...
(Date:11/6/2009)...nda for Arrowhead’s 2010 Personalized Medici...lace on February 22-24, 2010 in Philadelphia, has ...ll highlight key issues in forming partnerships an...ces. , Minneapolis, MN (P...’s 2010 Personalized Medicine Partnerships ...
(Date:11/5/2009)...PRNewswire/ -- The endangered black-footed ferrets...is rare carnivore feeds on prairie dogs. The pra... entire population die-offs in towns occur. The U...ted a ferret breeding program and has been releasi...tive habitat. Unfortunately, plague can sweep thr...
(Date:11/5/2009).... 5 ThermoGenesis Corp. ... products for processing and storing adult stem ce...of fiscal 2010. ,, For the quarter ended Septem...2 million, a 15 percent increase over revenues of ...Company said the key contributors to the growth in...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...nference Call Tomorrow (Tuesday) at 8:30 am EDT to... Valley Cottage, NEW YORK, September 10 XTL,Biop...E: XTL) today announced,the initiation of a Phase ... norepinephrine reuptake inhibitor (SNRI) - for th...ine is being developed for the treatment of diabet...
...ltern, a leading global research,organization, is ...,Chiltern,s Country Manager for the Czech Republic...e year award. The award ceremony was held in,Londo...om amongst his peers by a panel of judges who,revi...ccessful conclusion,of clinical trials. The judgin...
Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
Other Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
(Date:11/9/2009)...s inspired a 3.2m, three-year research project tha...security, energy and the environment. The Universi...QinetiQ have just signed a collaborative contract ...g physical sciences research. , Over the next t...y of Exeter and QinetiQ will work together to deve...
(Date:11/9/2009)...09 / b3c newswire / - Today, TNO, a Dutch contr...erican organization for contract research and cons... letter of intent with regard to TNOs dynamic in ...intent proposes a collaboration in which Seventh W...ion in North America. The TIM systems will be used...
(Date:11/9/2009)...leaders from around the world will gather in Bosto...ar Targets and Cancer Therapeutics International C...mation on important cancer therapies in developmen...it effectively we need a greater understanding of ...el," said Lewis Cantley, Ph.D., director of the ca...
Breaking Biology News(10 mins):£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Exponent to Announce Second Quarter 2009 Results 51709 1Elton John Billy Crystal Tony Bennett and Gladys Knight Help Starkey Hearing Foundation Raise More than 245 Million at Annual Fundraiser 51705 1Elton John Billy Crystal Tony Bennett and Gladys Knight Help Starkey Hearing Foundation Raise More than 245 Million at Annual Fundraiser 51705 2Elton John Billy Crystal Tony Bennett and Gladys Knight Help Starkey Hearing Foundation Raise More than 245 Million at Annual Fundraiser 51705 3Reminders Boost Mammography Appointments 51703 1Reminders Boost Mammography Appointments 51703 2
...ls have been little more than electronic versions ...the launch of PLoS ONE, which publishes primary re...pre- and post-publication peer review to maximize ...is published by the Public Library of Science (PLo...e the world,s scientific and medical literature a ...
...Many of them had narrow, pointed teeth, which were...wing them. But how did they then grind their food?... they were helped by stones which they swallowed. ...nd of ,gastric mill,. But this assumption does not...ties of Bonn and Tübingen have now proved. Their r...
... based on a combination of satellite data, compute...moke from Alaskan and Canadian forest fires as muc... away in Houston during a two-day period in July 2...in the Journal of Geophysical Research, offers sci...effects from pollutants generated thousands of mil...
Other Biology News:PLoS ONE is launched by the Public Library of Science 2PLoS ONE is launched by the Public Library of Science 3Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3NASA study: Alaskan fires affected Houston air quality in 2004 2NASA study: Alaskan fires affected Houston air quality in 2004 3
...nity Life Sciences can provide custom microplate c...croplate processing equipment that dispenses and w...mmodate virtually any lot size of the following fo... 8 and 12 well strips, 96 well microplate, ...
Cytomics FC 500 Series Flow Cytometry Systems from Beckman Coulter
Mynox Mycoplasma Elimination Reagent from Minerva Biolabs GmbH
Mynox Mycoplasma Elimination Reagent from Sigma-Aldrich
Biology Products: